Last reviewed · How we verify
Salidroside
Salidroside is a Small molecule drug developed by The Second Hospital of Shandong University. It is currently in Phase 2 development.
Salidroside is a glucoside of tyrosol found in the plant Rhodiola rosea, a small molecule compound. It has been studied in clinical trials, including those examining its effects on physical performance and fatigue in competitive football players, as well as its potential use in assisted reproductive technology.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Salidroside |
|---|---|
| Sponsor | The Second Hospital of Shandong University |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Combined Caffeine and Rhodiola Rosea on Aerial Duel Performance in Soccer (NA)
- Effects of Four-Week Rhodiola Rosea Supplementation on Physical Fitness, Neuromuscular Performance, and Decision-Making in Competitive Football Players (NA)
- Effect of Salidroside on Pregnancy Outcomes in High Childbearing Age Patients in Viro Fertilization (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Salidroside CI brief — competitive landscape report
- Salidroside updates RSS · CI watch RSS
- The Second Hospital of Shandong University portfolio CI
Frequently asked questions about Salidroside
What is Salidroside?
Who makes Salidroside?
What development phase is Salidroside in?
Related
- Manufacturer: The Second Hospital of Shandong University — full pipeline
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing